CCL22

Across TCGA pan-cancer cohorts, CCL22 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CCL22 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher CCL22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCL22 expression acts as an unfavorable survival marker.

ESCA and COAD are the cancer types where CCL22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.117	0.703	<.001	36	view →
COAD	DFS	Median	All	0.160	0.693	.020	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CCL22–ESCA (OS)

Open the ESCA breakdown →